CDR111, an experimental MS therapy designed to eliminate harmful B-cells, reached an early development milestone.
In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results